Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Stopped early · Phase 1

Conditions studied: Ulcerative Colitis

In brief

To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)

Key facts

Study ID

NCT01164904

Run by

Amgen

People needed

72

Starts

2010-07-01

Expected to finish

2013-03-01

Last updated by the study team

2013-07-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Research Site — Glendale, California, United States
• Research Site — Danbury, Connecticut, United States
• Research Site — Plymouth, Minnesota, United States
• Research Site — Duncansville, Pennsylvania, United States
• Research Site — Herston, Queensland, Australia
• Research Site — Adelaide, South Australia, Australia
• Research Site — Prahran, Victoria, Australia
• Research Site — Nedlands, Western Australia, Australia
• Research Site — Auckland, New Zealand
• Research Site — Christchurch, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.